Announcements

Silence Therapeutics plc (Nasdaq: SLN), a clinical-stage RNA medicine company incorporated in England and Wales, filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 10, 2026.

OPAL Fuels Inc. filed a current report on August 10, 2026, disclosing the issuance of a press release covering its financial results for the quarter ended June 30, 2026.

Jade Biosciences, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the Securities and Exchange Commission on August 10, 2026, disclosing a net loss of $96.1 million for the first half of the year and total assets …

Silence Therapeutics plc filed a current report on August 10, 2026, disclosing positive topline results from the Phase 2 SANRECO trial evaluating divesiran in polycythemia vera.

Keel Infrastructure Corp. (NASDAQ: KEEL), formerly known as Bitfarms Ltd., filed its quarterly report on Form 10-Q for the quarter ended June 30, 2026, with the SEC on August 10, 2026, disclosing its first full quarter as a U.S. domestic issuer following a corporate …

MoonLake Immunotherapeutics filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting a net loss of $131.5 million for the first half of the year and a significant increase in cash holdings compared to …

MoonLake Immunotherapeutics filed a Current Report on Form 8-K on August 10, 2026, disclosing its financial results for the quarter ended June 30, 2026, and announcing positive topline week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis.